

Reference: FOI.ICB-2627/106

Subject: Tirzepatide Access

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
A. NHS guidance says cohort 1 - patients with a BMI of 40 or above and four or more qualifying comorbidities - should have been offered access to tirzepatide in 2025/26. 1. How many patients in the ICB area are in cohort 1? 2. How many patients in this cohort have been offered treatment with tirzepatide? 3. How many have been prescribed tirzepatide? 4. How many have been offered/prescribed alternative weight-loss treatment?	1. An estimated 1469 patients meeting cohort 1 criteria in BNSSG area 2. 624 patients with assessed related code in General Practice 3. 611 patients prescribed tirzepatide by general practice from cohort 1 estimate since 23/6/25 4. The ICB does not hold this information
B. NHS guidance says cohort 2 - patients with a BMI of 40 or above and four or more qualifying comorbidities - should be offered access to tirzepatide in 2026/27. 1. How many patients in the ICB area are in cohort 2? 2. How many patients in this cohort have been offered treatment with tirzepatide? 3. How many have been prescribed tirzepatide? 4. How many have been offered/prescribed alternative weight-loss treatment?	1. AN estimated 2163 patients meeting cohort 2 criteria in BNSSG area 2. Cohort 2 not yet started 3. Cohort 2 not yet started 4. The ICB does not hold this information

The information provided in this response is accurate as of 19 June 2026 and has been approved for release by Dr Aananthakrishnan Raghuram, Chief Clinical Leadership and Delivery Officer (Medical) for NHS Bristol, North Somerset and South Gloucestershire ICB.